- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03537222
Quality of Life in Patients With Multiple Myeloma-validation Study
Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8032
- Onkozentrum Hirslanden
-
-
Thurgau
-
Münsterlingen, Thurgau, Switzerland, 8596
- Kantonsspital Münsterlingen
-
-
Zurich
-
Aarau, Zurich, Switzerland, 5001
- Kantonsspital Aarau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- informed consent as documented by signature
- confirmed histological diagnosis of multiple myeloma,
- age ≥ 18 years,
- mental capacity to give written informed consent
Exclusion Criteria:
- inability to communicate in German
- participation in another clinical study
- more than one cancer diagnosis
- mental illness (i.e. psychiatric diagnosis)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
MyPOS
|
Patients complete the MyPOS questionnaire on quality of life
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS)
Time Frame: upon enrollment
|
The primary outcome will be the scores on each item of the culturally-adapted Swiss-German MyPOS. Items are scored on a five-point Likert scale. For the analysis, the three subscales "Symptoms" (range: 0-52), "Emotions" (range:0-68) and "Healthcare Support" (range: 0-12) are assessed as well as the MyPOS total score (range: 0-132 ) by summing up the item scores ranging from 0-4. Higher scores reflect worse quality of life. The scores will be used to evaluate the psychometric properties of the culturally-adapted Swiss-German MyPOS:
|
upon enrollment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Julia Dratva, Prof.Dr.med, Zurich University of Applied Sciences
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- 97107155001701
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Myeloma Patient Outcome Scale (MyPOS)
-
Seoul National University HospitalSK Telecom ConsortiumCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedPrognosis of Neurological Outcome at 6 Months in Patients Undergoing Traumatic Brain InjuryFrance
-
Centre Hospitalier National d'Ophtalmologie des...Not yet recruitingAge-Related Macular Degeneration
-
Geisinger ClinicPatient-Centered Outcomes Research Institute; Penn State University; University... and other collaboratorsActive, not recruitingPediatric Obesity | Preventive Medicine | Mentoring | Food SupplyUnited States
-
Regina Elena Cancer InstituteCentro di Riferimento Oncologico - Aviano; Fondazione Salvatore Maugeri; Istituti... and other collaboratorsRecruitingQuality of Life | Psychological Distress | Breast Neoplasm FemaleItaly
-
University Hospital, Clermont-FerrandCompletedPain | Cancer | Substance UseFrance
-
Radboud University Medical CenterJeroen Bosch ZiekenhuisRecruitingPatient Engagement | Intensive Care Unit SyndromeNetherlands
-
Karolinska InstitutetSkandinaviska Forskningsstiftelsen för Åderbråck och andra VensjukdomarCompletedQuality of Life | Superficial Venous Insufficiency | Change After TreatmentSweden
-
Imam Abdulrahman Bin Faisal UniversityQatif Central HospitalRecruitingAnterior Cruciate Ligament | InjuriesSaudi Arabia
-
Suleyman Demirel UniversityCompleted